France – Healthcare, Regulatory and Reimbursement Landscape

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

GlobalData, the industry analysis specialist, has released its latest report, "France – Healthcare, Regulatory and Reimbursement Landscape". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in France. It identifies the key trends in the country’s healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData’s team of industry experts.

France is the second largest pharmaceutical and medical device market, in terms of value, in Europe after Germany. The French pharmaceutical market increased from €53.69B in 2015 to €60.05B in 2019 at a Compound Annual Growth Rate (CAGR) of 2.84%. In terms of US Dollars, the market increased from $59.54B in 2013 to $67.25B in 2020 at a CAGR of 3.09%. It is forecast to reach about $82.02B in 2025. The changing demographics, chronic and lifestyle diseases, incentives for innovation, universal health coverage, and early access to innovative medicines are the main factors driving the growth of the French pharmaceutical market.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in France, and includes:

An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers

Profiles and SWOT analyses of the major players in the pharmaceutical market: Bayer, Pfizer, Sanofi, Viatris, and Servier

Profiles and SWOT analyses of the major players in the medical device market: Abbott, Medtronic, Roche Diagnostics, EssilorLuxottica, and Air Liquide

An insightful review of the COVID-19 epidemiology, COVID-19 impact, and developments in healthcare market, HealthTech landscape, reimbursement, and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices

Detailed analysis of the country’s healthcare policy highlights, demographics, healthcare infrastructure, and healthcare expenditure

An overview of the opportunities for and challenges to growth in the French healthcare market

Reasons to Buy

This report will enhance your decision-making capability by allowing you to:

Develop business strategies by understanding the trends shaping and driving France’s healthcare market

Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact France’s healthcare market in the future

Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance

Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership

Table of Contents

1. Table of Contents

1.1List of Figures

1.2 List of Tables

2. Executive Summary

2.1 Executive Summary

2.2 Key Highlights – Facts about the French Healthcare Market

2.3 Key Highlights: Healthcare Startups in France

2.4 Key Events: French Healthcare Timeline, 2015-2021

2.5 Key Events: French Pharmaceutical Market

2.6 Key Events: M&As, VC & PE Deals, Global Pharmaceutical Market, 2019-2020

2.7 Key Events: Mergers and Acquisitions

2.8 Country Profile, France, 2020

3. Overview of Pharmaceutical Market

3.1 Pharmaceutical Market – Overview

3.2 Pharmaceutical Market – Exports

3.3 Pharmaceutical Market – Imports

3.4 Pharmaceutical Market – Supply Channels, France

3.5 Pharmaceutical Market – Market Segments

3.6 Major Therapeutic Areas, France

3.7 COVID-19 Epidemiology, France

3.8 COVID-19 Impact and Developments in the Healthcare Market, France

3.9 COVID-19 Clinical Trials Landscape, France

3.10 Pharmaceutical Market – Major Players

4. Overview of Medical Devices Market

4.1 Medical Device Market – Overview

4.2 Medical Devices Market – Major Players

5. Pharmaceutical and Medical Devices Market – Drivers and Barriers

5.1 Drivers

5.2 Barriers

6. Deal Analysis

6.1 Deal Analysis: Pharmaceutical Market, France, 2020-2021

6.2 Deal Analysis: Medical Device Market, France, 2020-2021

7. HealthTech Landscape

7.1 HealthTech Landscape, France

7.2 HealthTech Deals Landscape, France

7.3 Key HealthTech Deals, France

7.4 Adoption of Technology in Healthcare, France

7.5 Key Developments: HealthTech Against COVID-19 Crisis, France

7.6 Regulatory Scenario Covering Use of Technology in Healthcare, France

7.7 HealthTech Landscape: Benefits and Risks, France

8. Market Access

8.1 Overview of Healthcare System, France

8.2 Reimbursement of Medicinal Products, France

8.3 Reimbursement of Medical Devices, France

8.4 Overview of Insurance Providers, France

8.5 Healthcare Spending and Medicine Price Index, France

8.6 Pricing Policies, France

8.7 Regulatory Landscape, France

8.7.1 Overview of Regulatory Agencies

8.7.2 Marketing Authorization for Pharmaceutical Products, France

8.7.3 Marketing Authorization for Medical Devices, France

8.7.4 Intellectual Property Rights, Patent, France

8.7.5 Intellectual Property Rights, Trademark, France

8.7.6 Clinical Trial Regulation, France

8.7.7 Pharmaceutical Clinical Trials Landscape, France

8.7.8 Medical Devices Clinical Trials Landscape, France

8.7.9 Pharmaceutical Export and Import, France

8.7.10 Pharmaceutical Advertisement Regulations, France

8.7.11 Pharmaceutical Establishment Regulations, France

8.6.12 Pharmacy Regulations, France

8.7.13 Labeling and Packaging Regulations, France

9. Country Healthcare Landscape

9.1 French Healthcare Policy Highlights

9.2 Healthcare Facilities, France

9.3 Healthcare Parameters, France

9.4 Life Expectancy and Immunization Rate, France

9.5 Environmental Health, France

9.6 Healthcare Personnel, France

9.7 Disease Burden, France

9.8 Healthcare Expenditure, France

10 Trade Associations, France

11 Trade Fairs, France

12 Opportunities and Challenges

13 Appendix

13.1 Research Methodology

13.1.1 Coverage

13.1.2 Secondary Research

13.1.3 Forecasts

13.2 Bibliography

13.3 About GlobalData

13.4 Contact Us

13.5 Disclaimer

Table

Table 1: Approved Biosimilars, EU, 2020-2021

Table 2: Top Five Therapeutic Areas by Annual Revenue (%), France, 2019

Table 3: COVID-19 Indicators (Number of Cases), Global and France, 2020-2021

Table 4: COVID-19-Related Travel Restrictions, France, 2020-2021

Table 5: COVID-19 Vaccines Authorized, France, 2020-2021

Table 6: COVID-19 Vaccines Under Evaluation, France, 2021

Table 7: COVID-19 IVD Products (June ‘20- June ‘21), France, 2020-2021

Table 8: Medical Device Market, France, Major Segments ($B), 2020

Table 9: General Surgery Market, France, Revenue ($M) and Market Share (%) of Major Companies, 2020

Table 10: Cardiovascular Devices Market, France, Revenue ($M) and Market Share (%) of Major Companies, 2020

Table 11: Wound Care Management Market, France, Revenue ($M) and Market Share (%) of Major Companies, 2020

Table 12: Orthopedic Devices Market, France, Revenue ($M) and Market Share (%) of Major Companies, 2020

Table 13: Anesthesia and Respiratory Devices Market, France, Revenue ($M) and Market Share (%) of Major Companies, 2020

Table 14: Actual Clinical Benefit Levels, France, 2021

Table 15: Clinical Added Value Levels, France, 2021

Table 16: Reimbursement Rates for Medical Procedures and Services Covered by Health Insurance Schemes, France, 2021

Table 17: Wholesalers-distributors Margin, France, 2020

Table 18: Patent Fees, France, 2021

Table 19: Trademark Fees, France, 2021

Table 20: Outer Packaging of Solid Oral Forms, France, 2021

Table 21: Recommendations Specific to Small Packaging, France, 2021

Table 22: Primary Packaging of Solid Oral Forms, France, 2021

Table 23: Recommendations Specific to Small Blister Packs, France, 2021

Figures

Figure 1: Pharmaceutical Market, France, Revenue ($B and €B), 2013-2020

Figure 2: Medical Devices Market, France, Revenue ($B), 2015-2020

Figure 3: Healthcare Startups in France, 2021

Figure 4: Number of Deals (2019-2020)

Figure 5: 2019-2020 Deal Overview by Region

Figure 6: Country Profile, France, 2020

Figure 7: Pharmaceutical Market, France, Revenue ($B and €B), 2013-2020

Figure 8: Pharmaceutical Market, France, Revenue Forecast ($B and €B), 2021-2025

Figure 9: Pharmaceutical Exports ($B), France, 2013-2020

Figure 10: Top Export Partners, France, 2020

Figure 11: Pharmaceutical Imports ($B), France, 2013-2020

Figure 12: Top Import Partners, France, 2020

Figure 13: Pharmaceutical Supply Channel, France, 2019

Figure 14: % Share of Generics by Value, France, 2019

Figure 15: % Share of Generics by Volume, France, 2019

Figure 16: Marketing Authorizations (MA) for Generic Medicines, France, 2015-2019

Figure 17: Health Competitiveness Clusters, France, 2021

Figure 18: OTC Market, France, Revenue ($B), 2013-2020

Figure 19: OTC Market by Drug Category, France, Revenue ($M), 2020

Figure 20: Top Five Therapeutic Areas by Annual Revenue (%), France, 2019

Figure 21: COVID-19 Cases, France, 2020-2021

Figure 22: COVID-19 Deaths, France, 2020-2021

Figure 23: COVID-19 Fiscal Stimulus Timeline, France, 2020-2021

Figure 24: Vaccine Doses Administered per 1,000 People, France, 2021

Figure 25: COVID-19 Clinical Trials Count by Phase, France, 2020-2021

Figure 26: COVID-19 Clinical Trials Count by Trial Status, France, 2020-2021

Figure 27: Top Five COVID-19 Clinical Trials Sponsors by Trial Count, France, 2020-2021

Figure 28: Medical Devices Market, France, Revenue ($B), 2015-2020

Figure 29: Medical Devices Market, France, Revenue Forecast ($B), 2021-2025

Figure 30: Medical Device Market, France, Major Segments (%), 2020

Figure 31: General Surgery Market, France, Revenue ($B), 2017-2025

Figure 32: General Surgery Market, France, Market Share of Major Players (%), 2020

Figure 33: Cardiovascular Devices Market, France, Revenue ($B), 2017-2025

Figure 34: Cardiovascular Devices Market, France, Market Share of Major Players (%), 2020

Figure 35: Wound Care Management Market, France, Revenue ($B), 2017-2025

Figure 36: Wound Care Management Market, France, Market Share of Major Players (%), 2020

Figure 37: Orthopedic Devices Market, France, Revenue ($B), 2017-2025

Figure 38: Orthopedic Devices Market, France, Market Share of Major Players (%), 2020

Figure 39: Anesthesia and Respiratory Devices Market, France, Revenue ($B), 2017-2025

Figure 40: Anesthesia and Respiratory Devices Market, France, Market Share of Major Players (%), 2020

Figure 41: Diagnostics Market, France, Revenue ($B), 2015-2020

Figure 42: Diagnostics Market, France, Revenue Forecast ($B), 2021-2025

Figure 43: Medical Devices Market, Revenue ($B) of Major Companies, France, 2020

Figure 44: Deal Value and Deal Count, Pharmaceutical Market, France, 2020-2021

Figure 45: Deal Value and Deal Count Sub-types, Pharmaceutical Market, France, 2020-2021

Figure 46: Deal Value and Deal Count, Quarterly, Pharmaceutical Market, France, 2020-2021

Figure 47: Top Five Therapy Areas by Deal Value and Deal Count, Pharmaceutical Market, France, 2020-2021

Figure 48: M&A Deals by Therapy Area, Pharmaceutical Market, France, 2020-2021 (by Value ($M) and by Number)

Figure 49: VC Deals by Therapy Area, Pharmaceutical Market, France, 2020-2021 (by Value ($M) and by Number)

Figure 50: PE Deals by Therapy Area, Pharmaceutical Market, France, 2020-2021 (by Value ($M) and by Number)

Figure 51: Medical Devices Market Deals by Deal Value ($M), France, 2020-2021

Figure 52: Medical Devices Market Deals by Deal Count, France, 2020-2021

Figure 53: Medical Devices Market Deals Share by Deal Value, France, 2020-2021

Figure 54: Medical Devices Market Deals Share by Deal Count, France, 2020-2021

Figure 55: Top Five Therapy Area by Deal Value ($M), Medical Devices Market, France, 2020-2021

Figure 56: Top Five Therapy Area by Deal Count, Medical Devices Market, France, 2020-2021

Figure 57: M&A Deals by Therapy Area, Medical Devices Market, France, 2020-2021 (by Value ($M) and by Number)

Figure 58: VC Deals by Therapy Area, Medical Devices Market, France, 2020-2021 (by Value ($M) and by Number)

Figure 59: Number of Products in Development and Marketed by French HealthTech and Purposes, France, 2020

Figure 60: Adoption of eHealth Technologies, France, 2020

Figure 61: Deal Value ($B), HealthTech, France, 2020-2021

Figure 62: Deal Count (No. of Deals), HealthTech, France, 2020-2021

Figure 63: Type of Products Developed by HealthTech Companies Against COVID-19, France, 2020

Figure 64: Health Innovation Coalition Projects, France, 2020

Figure 65: Organization of the Health System, France, 2020

Figure 66: Reimbursement of Medicinal Products, France, 2020

Figure 67: Reimbursement of Medical Devices, France, 2021

Figure 68: Share of Benefits Provided by Social Security, France, 2019

Figure 69: Share of Benefits in Medical Care and Goods, France, 2019

Figure 70: Share of Benefits Provided by State, Local and CMU-C Based Organizations, France, 2019

Figure 71: Share of Benefits Provided by Complementary Organizations , France, 2019

Figure 72: OOP Expenditure (% of Total Expenditure on Health), France, 2012-2020

Figure 73: Annual Rate of Change (%), Health Price Index, France, 2012-2020

Figure 74: The Evolution of the Price of Drugs, France, 2018

Figure 75:ANSM Organizational Structure, France, 2019

Figure 76: Marketing Authorization for Pharmaceutical Products, EU, 2020

Figure 77: Centralized Procedure, EU, 2021

Figure 78: Decentralized Procedure, EU, 2021

Figure 79: Mutual Recognition Procedure, EU, 2021

Figure 80: National Procedure, France, 2019

Figure 81: Conformity Assessment of Class I Medical Devices, EU, 2019

Figure 82: Conformity Assessment of Class IIa Medical Devices, EU, 2019

Figure 83: Conformity Assessment of Class IIb Medical Devices, EU, 2019

Figure 84: Conformity Assessment of Class III Medical Devices, EU, 2019

Figure 85: European Patent Approval Process, EU, 2020

Figure 86: Unitary Patent Approval Process, EU, 2020

Figure 87: Different Management Procedures for Category 1 Clinical Trials of Medicinal Products, France, 2021

Figure 88: Different Management Procedures for Category 1 Clinical Trials of Innovative Therapy Drugs, France, 2021

Figure 89: Different management procedures for Category 1 clinical trials of MD/IVD, France, 2021

Figure 90: Pharmaceutical Clinical Trials Count by Trial Status, France, 2020-2021

Figure 91: Pharmaceutical Clinical Trials Count by Therapy Area, France, 2020-2021

Figure 92: Pharmaceutical Clinical Trials Count by Phase, France, 2020-2021

Figure 93: Top Five Pharmaceutical Clinical Trial Sponsors by Count, France, 2020-2021

Figure 94: Medical Devices Clinical Trials Count by Trial Status, France, 2020-2021

Figure 95: Medical Devices Clinical Trials Count by Indication, France, 2020-2021

Figure 96: Medical Devices Clinical Trials Count by Category, France, 2020-2021

Figure 97: Top Five Medical Devices Clinical Trial Sponsors by Count, France, 2020-2021

Figure 98: Number of Hospitals, France, 2012-2018

Figure 99: Number of Diagnostic Equipment, France, 2015-2020

Figure 100: Hospital Beds (per 1,000 population), France, 2012-2018

Figure 101: Acute Care Hospital Beds (per 1,000 population), France, 2012-2018

Figure 102: Psychiatric Care Hospital Beds (per 1,000 population), France, 2012-2018

Figure 103: Life Expectancy at Birth (Years), France, 2012-2018

Figure 104: Immunization Rate (%), France, 2012-2019

Figure 105: Mean Population Exposure to PM2.5 (µg per m3), France, 2012-2019

Figure 106: CO2 Emissions (Million Tons), France, 2012-2019

Figure 107: Physicians (per 1,000 population), France, 2012-2018

Figure 108: Dentists (per 1,000 population), France, 2012-2018

Figure 109: Pharmacists (per 1,000 population), France, 2012-2018

Figure 110: Nurses (per 1,000 population), France, 2012-2018

Figure 111: Major Causes of Mortality (per 100,000 population), France, 2019

Figure 112: Major Causes of Male Mortality (per 100,000 population), France, 2019

Figure 113: Major Causes of Female Mortality (per 100,000 population), France, 2019

Figure 114: DALYs by Major Disease (per 100,000 population), France, 2019

Figure 115: Healthcare Expenditure as Percentage of GDP (%), France, 2012-2019

Figure 116: Health Expenditure Share (% of Total Health Spending), France, 2012-2019

Figure 117: Healthcare Expenditure Components by Function (% of Total Health Expenditure), France, 2018

Figure 118: Pharmaceutical Spending (% of Total Health Spending), France, 2012-2018

Frequently asked questions

France – Healthcare, Regulatory and Reimbursement Landscape thematic reports
Currency USD
$1,995

Can be used by individual purchaser only

$5,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

France – Healthcare, Regulatory and Reimbursement Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at France – Healthcare, Regulatory and Reimbursement Landscape in real time.

  • Access a live France – Healthcare, Regulatory and Reimbursement Landscape dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.